Michael Schmidt
Stock Analyst at Guggenheim
(3.33)
# 926
Out of 4,778 analysts
95
Total ratings
50.72%
Success rate
1.81%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Schmidt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VSTM Verastem | Maintains: Buy | $13 → $14 | $6.57 | +113.09% | 3 | Mar 24, 2025 | |
| IMNM Immunome | Maintains: Buy | $35 → $25 | $7.35 | +240.14% | 2 | Mar 20, 2025 | |
| MRUS Merus | Reiterates: Buy | $109 | $46.57 | +134.06% | 4 | Mar 18, 2025 | |
| INCY Incyte | Downgrades: Neutral | $92 | $62.01 | +48.36% | 5 | Mar 18, 2025 | |
| ARVN Arvinas | Maintains: Buy | $57 → $32 | $8.08 | +296.04% | 4 | Mar 13, 2025 | |
| LEGN Legend Biotech | Reiterates: Neutral | n/a | $34.51 | - | 1 | Mar 12, 2025 | |
| AVBP ArriVent BioPharma | Initiates: Buy | $45 | $18.95 | +137.53% | 1 | Mar 10, 2025 | |
| ORIC ORIC Pharmaceuticals | Reiterates: Buy | n/a | $6.81 | - | 5 | Feb 26, 2025 | |
| CMPX Compass Therapeutics | Initiates: Buy | $12 | $2.15 | +458.79% | 1 | Feb 24, 2025 | |
| EXEL Exelixis | Reiterates: Buy | $42 | $37.39 | +12.33% | 10 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $0.55 | - | 1 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $78 | $47.08 | +65.68% | 1 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $1.63 | +515.38% | 3 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $92.48 | - | 2 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $20 | $4.61 | +333.84% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $82 → $87 | $38.44 | +126.33% | 2 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $8 | $1.87 | +327.81% | 3 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $3 | $0.25 | +1,123.49% | 2 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $29.41 | - | 3 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $3.58 | +235.66% | 1 | Aug 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.42 | - | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.67 | - | 2 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7 | $0.43 | +1,514.39% | 2 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.60 | - | 1 | Jan 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $34 | $11.75 | +189.36% | 4 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $42 | $13.26 | +216.74% | 2 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 | $0.89 | +2,147.19% | 3 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $19.68 | - | 2 | Jan 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $1.52 | +1,550.17% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $5.85 | +412.82% | 1 | Jul 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $1.93 | +1,247.15% | 1 | May 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.33 | - | 2 | Apr 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $3.80 | - | 4 | Mar 5, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $80 | $30.95 | +158.52% | 5 | Feb 15, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $5.55 | - | 6 | Jan 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $4 → $5.5 | $3.37 | +63.20% | 2 | Nov 7, 2017 |
Verastem
Mar 24, 2025
Maintains: Buy
Price Target: $13 → $14
Current: $6.57
Upside: +113.09%
Immunome
Mar 20, 2025
Maintains: Buy
Price Target: $35 → $25
Current: $7.35
Upside: +240.14%
Merus
Mar 18, 2025
Reiterates: Buy
Price Target: $109
Current: $46.57
Upside: +134.06%
Incyte
Mar 18, 2025
Downgrades: Neutral
Price Target: $92
Current: $62.01
Upside: +48.36%
Arvinas
Mar 13, 2025
Maintains: Buy
Price Target: $57 → $32
Current: $8.08
Upside: +296.04%
Legend Biotech
Mar 12, 2025
Reiterates: Neutral
Price Target: n/a
Current: $34.51
Upside: -
ArriVent BioPharma
Mar 10, 2025
Initiates: Buy
Price Target: $45
Current: $18.95
Upside: +137.53%
ORIC Pharmaceuticals
Feb 26, 2025
Reiterates: Buy
Price Target: n/a
Current: $6.81
Upside: -
Compass Therapeutics
Feb 24, 2025
Initiates: Buy
Price Target: $12
Current: $2.15
Upside: +458.79%
Exelixis
Feb 12, 2025
Reiterates: Buy
Price Target: $42
Current: $37.39
Upside: +12.33%
Jan 22, 2025
Reiterates: Buy
Price Target: n/a
Current: $0.55
Upside: -
Jan 8, 2025
Maintains: Buy
Price Target: $80 → $78
Current: $47.08
Upside: +65.68%
Dec 12, 2024
Reiterates: Buy
Price Target: $10
Current: $1.63
Upside: +515.38%
Dec 11, 2024
Reiterates: Buy
Price Target: n/a
Current: $92.48
Upside: -
Dec 6, 2024
Reiterates: Buy
Price Target: $20
Current: $4.61
Upside: +333.84%
Dec 3, 2024
Maintains: Buy
Price Target: $82 → $87
Current: $38.44
Upside: +126.33%
Nov 15, 2024
Maintains: Buy
Price Target: $12 → $8
Current: $1.87
Upside: +327.81%
Nov 15, 2024
Maintains: Buy
Price Target: $4 → $3
Current: $0.25
Upside: +1,123.49%
Oct 7, 2024
Downgrades: Neutral
Price Target: n/a
Current: $29.41
Upside: -
Aug 28, 2024
Initiates: Buy
Price Target: $12
Current: $3.58
Upside: +235.66%
May 15, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.42
Upside: -
Mar 14, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.67
Upside: -
Feb 29, 2024
Upgrades: Buy
Price Target: $7
Current: $0.43
Upside: +1,514.39%
Jan 5, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.60
Upside: -
Nov 8, 2023
Maintains: Buy
Price Target: $40 → $34
Current: $11.75
Upside: +189.36%
Jul 25, 2023
Maintains: Buy
Price Target: $40 → $42
Current: $13.26
Upside: +216.74%
Jun 27, 2023
Downgrades: Neutral
Price Target: $20
Current: $0.89
Upside: +2,147.19%
Jan 3, 2022
Downgrades: Neutral
Price Target: n/a
Current: $19.68
Upside: -
Aug 10, 2021
Initiates: Buy
Price Target: $25
Current: $1.52
Upside: +1,550.17%
Jul 19, 2021
Initiates: Buy
Price Target: $30
Current: $5.85
Upside: +412.82%
May 18, 2021
Initiates: Buy
Price Target: $26
Current: $1.93
Upside: +1,247.15%
Apr 28, 2021
Downgrades: Neutral
Price Target: n/a
Current: $1.33
Upside: -
Mar 5, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $3.80
Upside: -
Feb 15, 2019
Upgrades: Outperform
Price Target: $80
Current: $30.95
Upside: +158.52%
Jan 17, 2019
Initiates: Outperform
Price Target: n/a
Current: $5.55
Upside: -
Nov 7, 2017
Maintains: Market Perform
Price Target: $4 → $5.5
Current: $3.37
Upside: +63.20%